Previous Article | Next Article 
Molecular and Cellular Biology, September 1998, p. 5425-5434, Vol. 18, No. 9
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
A Role for SRp54 during Intron Bridging of Small
Introns with Pyrimidine Tracts Upstream of the Branch Point
Catharine F.
Kennedy,1
Angela
Krämer,2 and
Susan M.
Berget1,*
Verna and Marrs McLean Department of
Biochemistry, Program in Cell and Molecular Biology, Baylor College
of Medicine, Houston, Texas 77030,1 and
Département de Biologie Cellulaire, Sciences III,
Université de Genève, CH-1211 Geneva 4, Switzerland2
Received 5 February 1998/Returned for modification 24 March
1998/Accepted 25 May 1998
 |
ABSTRACT |
One of the earliest steps in pre-mRNA recognition involves binding
of the splicing factor U2 snRNP auxiliary factor (U2AF or MUD2 in
Saccharomyces cerevisiae) to the 3' splice site region. U2AF interacts with a number of other proteins, including members of
the serine/arginine (SR) family of splicing factors as well as splicing
factor 1 (SF1 or branch point bridging protein in S. cerevisiae), thereby participating in bridging either exons or
introns. In vertebrates, the binding site for U2AF is the
pyrimidine tract located between the branch point and 3'
splice site. Many small introns, especially those in nonvertebrates,
lack a classical 3' pyrimidine tract. Here we show that a
59-nucleotide Drosophila melanogaster intron contains
C-rich pyrimidine tracts between the 5' splice site and
branch point that are needed for maximal binding of both U1 snRNPs and
U2 snRNPs to the 5' and 3' splice site, respectively, suggesting that
the tracts are the binding site for an intron bridging factor. The
tracts are shown to bind both U2AF and the SR protein SRp54 but not
SF1. Addition of a strong 3' pyrimidine tract downstream of
the branch point increases binding of SF1, but in this context, the
upstream pyrimidine tracts are inhibitory. We suggest that
U2AF- and/or SRp54-mediated intron bridging may be an alternative early
recognition mode to SF1-directed bridging for small introns, suggesting
gene-specific early spliceosome assembly.
 |
INTRODUCTION |
Pre-mRNA splicing is a conserved
process occurring in a wide variety of eucaryotes with differing
exon/intron architectures (reviewed in references 4, 6, 9, 15,
20, and 26). Vertebrates typically have
small exons and large introns. Nonmetazoans frequently have the
opposite genetic organization, with introns smaller than the minimum
permissible for splicing of a vertebrate intron. Drosophila
melanogaster possesses a mixture of these two classes of intron
sizes (16, 23). In addition, more than half of the small
introns in Drosophila are missing a prominent
vertebrate splicing signal, the 3' polypyrimidine tract
(23). For these reasons, Drosophila
provides a model system in which to study potential mechanistic
variations operating during recognition of splicing signals.
In the general model of early vertebrate spliceosome complex assembly,
U1 snRNP binds to the 5' splice site and U2 snRNP auxiliary factor
(U2AF) binds to the 3' polypyrimidine tract, thereby
facilitating U2 snRNP interaction with the branch point. Various
members of the serine/arginine (SR) family of proteins may participate
by promoting or stabilizing these interactions (reviewed in references 13, 22, and 31). This family of
proteins may also act as exon or intron bridging factors via their
SR-mediated interaction with SR domains on the small subunit of U2AF
(U2AF35) and the U1 70K protein (32, 33, 38).
SF1, originally discovered as an essential splicing factor in
reconstitution assays (19), has also been observed to bind
to the branch point (7, 8). In yeast, BBP (branch point
bridging protein), the ortholog to SF1, functions as an intron bridging
factor via interactions with U1 snRNP-associated proteins and the large
subunit of U2AF (U2AF65) (1, 2). It is assumed
that vertebrate SF1 can play a similar role, although the mammalian
equivalents to the yeast U1 snRNP proteins that interact with BBP have
not yet been identified. Furthermore, the relationship between bridging
by SR proteins and that afforded by SF1 is unclear.
We have previously examined the cis-acting sequences
required for efficient splicing of a constitutively spliced small
(59-nucleotide [nt]) intron from the D. melanogaster
mle gene that lacks a well-defined pyrimidine tract
between the branch point and 3' splice site (18, 29).
Assembly of initial ATP-dependent spliceosomes (complex A) on the
mle intron requires both the 5' and 3' splice sites, suggesting concerted recognition of the entire intron (29). Instead of a classic pyrimidine tract, the mle
intron contains two C-rich tracts located between the 5' splice site
and branch point that are necessary for efficient splicing of this
intron (18). In addition to a requirement for maximal
splicing efficiency, the pyrimidine stretches are also
necessary for binding of U2AF, interaction of factors with the 5'
splice site, and proper assembly of the active spliceosome, suggesting
that these sequences affect early assembly events at both ends of this
small intron. Interestingly, the upstream C-rich tracts are inhibitory
if a classical 3' pyrimidine tract is introduced
between the branch point and 3' splice site (18). This
observation suggests competing pathways of factor binding to this
substrate and also raises the possibility of alternative gene-specific modes of association of constitutive factors with introns.
Here we demonstrate that both U2AF and an SR protein, SRp54, interact
with the C-rich tracts in the mle intron. The central location of the pyrimidine tracts, their importance for
maximal splicing, and the ability of human SRp54 to interact with
U2AF65 instead of U2AF35 (37)
suggested that the binding of SRp54 to the tracts could replace SF1 in
bridging this intron. Immunoprecipitation studies using an antibody
specific for SF1 indicated that SF1 did not contact mle
precursor RNA unless a pyrimidine tract was introduced downstream of the branch point. Furthermore, antibodies against either
SRp54 or U2AF immunoprecipitated both halves of a precleaved mle splicing substrate, suggesting that these factors either
directly or indirectly interact with both the 5' and 3' splice sites.
We suggest that SRp54 participates in bridging the small mle
intron via its ability to bind both the C-rich tracts and the large
subunit of U2AF.
 |
MATERIALS AND METHODS |
Plasmids and oligonucleotides.
The following minigenes
contained all or part of the first intron from the D. melanogaster mle gene, along with 56 nt of the first exon and 96 nt of the second exon. The wild-type mle substrate contained
the entire 59-nt intron. Mle-py1,2, mle+py, and mle-py1,2+py were
identical to the wild-type pre-mRNA except for the introduced mutations
indicated in Fig. 1, which have been described previously (18). Mutants were constructed by mutagenic PCR. The
deletion mutants 5'ss+py and 5'ss-py contained 56 nt of exon 1 plus the first 38 nts of the intron, with wild-type and mutant C-rich tracts, respectively. Mle
5' lacked nt +1 to +8 of the intron in the context of the wild-type mle substrate. Mle5'mt contained the 5'
splice site nucleotides GGTA (
1 to +3) mutated to TTCG. The series of mle intron expansion substrates was constructed by the
addition of a NcoI site at either +39 (BP65) or +10 (5'65)
of the wild-type intron via PCR. Insertion of 15 or 30 nt of
Drosophila troponin T intron sequences (between the
TaqI and NlaIII sites in intron 7) into the
NcoI site of BP65 or 5'65, respectively, made BP80 and BP95
or 5'80 and 5'95. Readdition of C-rich tracts to the expansion
constructs was accomplished by insertion of a fragment from the
mle intron (nt +1 to +38) containing both tracts and the
natural sequence between them into the NcoI site. Both
wild-type (ResWT) and mutant (ResMT) versions of the intron were
inserted. The sequences of all plasmids were verified by using a Thermo Sequenase Radiolabeled Terminator Cycle Sequencing kit (Amersham Life
Science, Inc.). The A62 substrate was created by deleting +8 to +65 of
the MINX splicing substrate (27) to shorten the 120-nt
intron to 62 nt.
The following DNA or RNA oligonucleotides containing sequences from the
mle intron were obtained from Gibco BRL: a DNA
oligonucleotide complementary to +7 to +17 of the mle
intron, and RNA oligonucleotides corresponding to the wild-type
(CUCCCCCaggcgugUUUCCC) or mutant (CUGGCCCaggcgugUUAGCC) C-rich
tracts. Reverse transcriptase (RT)-mediated PCR (RT-PCR)
oligonucleotides included 5' primers complementary to nt 131 to 148 or
183 to 200 of the Drosophila or human SRp54 N-terminal RNA
recognition motif (RRM), respectively. Drosophila 3' primers
were complementary to nt 683 to 700 (spacer region) or 860 to 877 (a
portion of the antigenic peptide). The human 3' primer corresponded to
nt 708 to 728, which also encode a portion of the peptide to which the
anti-SRp54 antibody was raised.
In vitro spliceosome assembly.
Splicing reaction mixtures
consisting of 6.5 fmol of radiolabeled substrate, 50% D. melanogaster Schneider 2 (S2) nuclear extract, 1.6 mM
MgCl2, 20 mM phospho-L-arginine, 1.2 mM
dithiothreitol, 1.2% polyethylene glycol, and 2 mM ATP were incubated
at 22°C as described previously (18). Aliquots were taken
at the indicated time points. Spliceosome complexes were analyzed by
the addition of heparin to a final concentration of 0.2 mg/ml and
electrophoresis on native RNP gels (29).
UV cross-linking and competition.
In vitro assembly reaction
mixtures were incubated at 22°C for 7 min before the addition of
heparin to a final concentration of 2 mg/ml. Mixtures were transferred
to ice and UV irradiated immediately for 10 min. Reactions were
subsequently digested with RNase A at 37°C for 30 min. Labeled
proteins were displayed on sodium dodecyl sulfate-10% polyacrylamide
gels and visualized by autoradiography. Competition of cross-linking
used unlabeled competitor RNA oligonucleotides, corresponding to either
wild-type or mutant C-rich tracts, described above, added at time zero. The amount of competitor added was 0, 50, 100, or 200 pmol.
Immunoprecipitations and immunoblotting.
Immunoprecipitations of cross-linked proteins, assembled spliceosomes,
and RNA oligonucleotides were performed with antibodies against the
50-kDa subunit of Drosophila U2AF, provided by D. Rio
(17), antipeptide antibodies A and B against the human
SRp54, provided by N. Chaudhary (12), or anti-SF1
antibodies. The SF1 antibodies were two polyclonal rabbit sera raised
against a His-tagged recombinant fragment of human SF1 that includes
amino acids 2 to 320, a region of SF1 in which the human and
Drosophila proteins are highly homologous (22a).
Immunoprecipitation of precleaved radiolabeled pre-mRNA substrates was
conducted by incubating the assembly reactions at 22°C for 7 min
before the addition of RNase H and a DNA oligonucleotide complementary
to nt +7 to +17 of the mle intron. This mixture was then
incubated at 30°C for 3 min before the addition of anti-SRp54 or
anti-U2AF antibody. All immunoprecipitations were conducted by using
protein A-Sepharose (Pharmacia) in a buffer consisting of 20 mM NaCl,
50 mM Tris-HCl (pH 7.5), and 0.05% Nonidet P-40. Immunoprecipitates
were washed in this same buffer before elution in protein or RNA
sample buffer. For Western blotting, transfer and detection
procedures were performed as described in the PolyScreen instruction
manual (Dupont).
5' splice site protection.
To detect protein interactions at
the mle 5' splice site, an oligonucleotide complementary to
this region was added in excess along with RNase H after splicing
complex assembly had been allowed to proceed for the indicated amount
of time. After incubation at 30°C for 20 min to direct cleavage of
the substrate, RNA was prepared for electrophoresis on a 5% denaturing
polyacrylamide gel.
Cloning of Drosophila SRp54.
Drosophila
SRp54 cDNA was cloned by obtaining an EST (epitope sequence tag)
plasmid (LD 13325) from the Berkley Drosophila Genome Project/HHMI EST
Project. This clone was then fully sequenced by using a Thermo
Sequenase Radiolabeled Terminator Cycle Sequencing kit (Amersham Life
Science), and its amino acid sequence was directly compared to both the
human SRp54 amino acid sequence and the entire database, using the
Blast+Beauty, Align, or ClustalW computer program.
RT-PCR.
RT-PCRs were performed on total RNA isolated from
either S2 cells, Drosophila third-instar larvae (male and
female), or HeLa cells. The 5' primer used in the reactions
containing S2 or larval RNA corresponded to nt 131 to 148 of the
Drosophila cDNA (dSRp54 RRM), and the 3' primer was
complementary to either nt 683 to 700 (dSRp54 spacer region) or 860 to
877 (dSRp54 antigenic peptide) of the cDNA. Primers used to amplify the
HeLa RNA were complementary to nucleotides 183 to 200 (hSRp54 RRM) and
nucleotides 708 to 728 (antigenic peptide) of the human SRp54 cDNA.
Reverse transcription was performed with 1 µg of both the appropriate
RNA and 3' primer, 10 nmol of deoxynucleoside triphosphates and avian
myeloblastosis virus RT (Promega) at 50°C for 30 min under standard
buffer conditions. To begin the PCR, 1 µg of the 5' primer as well as
recombinant Taq polymerase (Perkin-Elmer) was added. The
reaction cycled 30 times between 94°C for 40 s, 55°C for
40 s, and 72°C for 1 min, and the reaction product was then
subjected to electrophoresis on an ethidium bromide-stained 1% agarose
gel.
Nucleotide sequence accession number.
The
Drosophila SRp54 sequence has been assigned GenBank
accession no. AF055719.
 |
RESULTS |
The SR protein SRp54 cross-links to the mle intron, and
its binding is dependent on wild-type C-rich tracts located upstream of
the branch point.
We have previously observed that two short
pyrimidine tracts located upstream of the branch point
within the small mle intron are necessary for maximal
spliceosome assembly and association of U2AF (18). The
sequences of these tracts (designated py1 and py2) and available
mutations (
py1,2, +py, and
py1,2+py) are indicated in Fig.
1. Despite the requirement of the tracts for maximal U2AF binding, the tract sequences (CUCCCCC and UUUCCC) do
not resemble optimal binding sites for U2AF (10, 28),
suggesting the participation of another factor during early pre-mRNA
recognition.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 1.
Sequence of the mle intron. (A) Top, diagram
of the mle intron depicting the locations of various
splicing signals. The two upstream C-rich pyrimidine tracts
located between the 5' splice site and branch point are designated py1
and py2. The poor pyrimidine tract located downstream of
the branch point is labeled py3. Bottom, sequences of the wild-type and
mutant pyrimidine tracts. The introduced point mutations
are underlined. Mutation of the upstream tracts is denoted
py1,2; improvement of the downstream pyrimidine tract
is denoted +py. (B) Other substrates used in
immunoprecipitation and/or UV cross-linking experiments. The C-rich
tracts are represented by the letter p, while mutations are
indicated by an X. (C) Sequences of both the wild-type and mutant
RNA oligonucleotides used in competition and immunoprecipitation
experiments.
|
|
We used UV cross-linking to identify additional proteins binding to the
upstream pyrimidine tracts. UV cross-linking revealed
a
protein of approximately 75 kDa (p75) whose cross-linking tracked
with
the presence of the upstream C-rich tracts. This protein
cross-linked
to the wild-type
mle pre-mRNA (Fig.
2A, lane 1).
Mutation of the upstream
pyrimidine tracts depressed cross-linking
of p75 in the
context of either the full-length intron or a partial
intron containing
only the 5' splice site and upstream C-rich
tracts (Fig.
2A, lanes 6 and 3, respectively). Interestingly,
interaction of p75 with the
substrate was not dependent on the
presence of either a 5' splice site
(Fig.
2A, lanes 4 and 5) or
a 3' splice site (Fig.
2A, lane 2).
Instead, observation of cross-linking
required only the presence of the
wild-type C-rich pyrimidine
tracts (Fig.
2A; compare lanes
2 and 3). Improving the 3' splice
site to provide a more classical
pyrimidine tract downstream of
the branch point did not
eliminate association of p75 (Fig.
2A,
lane 7), although it did cause
the appearance of another interacting
protein, p70 (see below).
Cross-linking of p75 to the
mle substrate
occurred early in
the reaction prior to assembly of complex A
and did not require ATP
(data not shown). Thus, it appears that
there is a factor, p75,
interacting with the C-rich pyrimidine
tracts during the
earliest steps of spliceosome assembly.

View larger version (81K):
[in this window]
[in a new window]
|
FIG. 2.
A 75-kDa protein interacts with the upstream C-rich
tracts. (A) UV cross-linking of proteins to the wild-type (WT) and
mutant mle introns. The position of a 75-kDa protein (p75)
whose cross-linking is dependent on the presence of wild-type upstream
pyrimidine tracts is marked by an arrow. The precursor RNAs
used are diagrammed in Fig. 1. A second band appearing below p75 in
lane 7 and designated p70 in the text is discussed with reference to
Fig. 5. Positions of markers here and in all other relevant figures are
indicated in kilodaltons. (B) Competition of cross-linking of
p75 by an oligonucleotide containing wild-type but not mutant C-rich
pyrimidine tracts. Cross-linking of p75 to mle
wild-type precursor RNA was monitored in the presence of increasing
amounts of RNA oligonucleotides corresponding to either wild-type or
mutant C-rich tracts. The amount of competitor used is indicated above
the corresponding lane, and the competitor sequences are shown in Fig.
1C. The bands corresponding to p75 and U2AF are indicated, and
positions of markers are shown on the right.
|
|
The necessity of the pyrimidine tracts for p75 binding was
tested in competition experiments in which UV cross-linking of
p75 to
radiolabeled wild-type
mle precursor RNA was assessed in
the
presence of increasing amounts of unlabeled competitor RNA
oligonucleotides corresponding to either wild-type or mutant C-rich
tracts (Fig.
2B). UV cross-linking of p75 to the
mle
substrate
was competed by a wild-type RNA oligonucleotide but not by
equivalent
concentrations of a competitor oligonucleotide containing
the
py1,2 mutations (Fig.
2B; compare lanes 1 to 4 with 5 to 8).
Therefore,
the loss of p75 cross-linking to the
mle
pre-mRNA containing mutated
pyrimidine tracts reflected
a loss of binding and not an inability
to detect association due to the
absence of nucleotides necessary
for establishing the chemical
cross-link. It should be noted that
the wild-type RNA oligonucleotide,
but not the mutant oligonucleotide,
also competed cross-linking of
U2AF. This observation agrees with
previous published results
demonstrating that the elements influence
association of U2AF with the
mle intron (
18). Therefore, the
upstream
pyrimidine tracts appear to interact with two
trans-acting
factors, U2AF and a protein of approximately 75 kDa.
Several proteins, including SF1 (
2), SRp54 (
37),
and other members of the SR family of proteins, are known to interact
with U2AF. The identity of p75 was thus investigated by conducting
immunoprecipitation experiments using antibodies specific for
proteins
known to interact with U2AF. One such antibody was an
antipeptide
antibody raised against human SRp54 and specific for
a region of the
protein between the RRM and SR domains (
12).
This antibody
recognized two bands of 70 to 75 kDa on Western
blots of
Drosophila S2 or HeLa extract (Fig.
3B, lane 1 or 4),
indicating the presence
of SRp54 in
Drosophila. The multiple bands
presumably
reflect differential levels of phosphorylation of SRp54
because
phosphatase treatment or purification of extract proteins
resulted in
increased protein mobility (data not shown and Fig.
3B, lanes 2 and 3).

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 3.
p75 is Drosophila SRp54. (A)
Immunoprecipitation of cross-linked proteins with an antipeptide
antibody specific for SRp54. Products of UV cross-linking reactions
using wild-type (WT) or mutant mle precursor RNAs were
immunoprecipitated from S2 nuclear extract with anti-SRp54 antibodies
specific for amino acids 209 to 225 of the human protein (antibody A
[12]). The positions of Drosophila SRp54
and of the markers are indicated. Here and in all other relevant
figures, total X-link (lane 1) indicates all of the proteins that UV
cross-link to mle wild-type precursor mRNA. (B) Western
blot of Drosophila and HeLa nuclear extracts using the
antipeptide anti-SRp54 antibody. Lane 1, Drosophila S2
nuclear extract proteins; lanes 2 and 3, HeLa nuclear extract proteins
partially purified on poly(U)-Sepharose; lane 4, HeLa nuclear proteins.
The multiple bands presumably reflect differential phosphorylation of
the SR domain. Similar results for both blotting and
immunoprecipitation were observed with a different anti-SRp54
antipeptide antibody (antibody B [12]). Markers are
indicated.
|
|
Use of the antibody to immunoprecipitate UV cross-linked proteins
binding to the
mle substrate indicated that SRp54 binds
to
the
mle intron. The anti-SRp54 antibody recognized a UV
cross-linked
protein of 75 kDa when wild-type
mle was used
as the splicing
substrate (Fig.
3A). p75 comigrated with the band
identified in
Fig.
2A, suggesting that p75 is SRp54. No band was
evident when
mle-py1,2 was used as the substrate, indicating that
cross-linking
of
Drosophila SRp54 required the upstream
pyrimidine tracts and
also further confirmed the identity
of the protein being monitored
in our mutation experiments in Fig.
2A
as SRp54. These results
support the idea that the C-rich
pyrimidine tracts bind SRp54.
Antibodies against SRp54 and U2AF immunoprecipitate RNA
oligonucleotides corresponding to the C-rich tracts.
To more fully
determine which factors interact with the upstream
pyrimidine stretches, further immunoprecipitation
experiments were carried out. In these studies, RNA
oligonucleotides containing mle intron sequence from nt +19
to +38, either wild type or mutated for the upstream
pyrimidine tracts (py1,2 mutant), were incubated in S2
extract and anti-SRp54 or anti-U2AF antibodies were used to
immunoprecipitate the radiolabeled oligonucleotides. As can be seen in
Fig. 4, the wild-type RNA oligonucleotide
was immunoprecipitated with either antibody (lanes 3 and 5). This
ability was lost when the C-rich tracts were mutated (lanes 4 and 6).
The results from this experiment support the hypothesis that both
SRp54 and U2AF interact with the C-rich tracts located between the 5'
splice site and branch point in the mle intron.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 4.
Both SRp54 and U2AF interact with the upstream C-rich
tracts. RNA oligonucleotides corresponding to either a wild-type (WT;
lanes 2, 3, and 5) or mutant (MT; lanes 4 and 6) C-rich tract
(diagrammed at the bottom) were incubated in S2 extract for 7 min and
then immunoprecipitated with either anti-SRp54 (lanes 3 and 4) or
anti-U2AF (lanes 5 and 6) antibody. Immunoprecipitated RNA was
displayed on a 10% denaturing polyacrylamide gel. The position of the
immunoprecipitated oligonucleotide is indicated. Markers (nucleotide
lengths indicated) are in lanes 1 and 7.
|
|
The Drosophila homolog of SRp54 is similar to
human SRp54 within the RNA binding domain.
Only the human
version of SRp54 has been reported to date (12). A
computer search of the Berkley Drosophila Genome Project revealed an
EST clone that showed homology with the human SRp54 RRM region.
The clone (LD 13325) was provided, and sequencing revealed that it
contained a likely cDNA for Drosophila SRp54. Figure
5A compares the sequences of the human
and Drosophila proteins. The RRMs located at the N termini
of the two proteins exhibited 60% identity and 83.8% similarity,
indicating that the Drosophila and human proteins could
exhibit very similar RNA binding specificity. Such strong conservation
of the RRM between the human and Drosophila proteins is
striking, given the observation that the RRM of human SRp54 shares only
17 to 21% identity with other human SR proteins (37). The
SR regions of the two proteins were also similar.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 5.
Drosophila SRp54. (A) The sequence of
Drosophila SRp54 compared with the sequence of human SRp54.
The N-terminal RRM is underlined; the SR region is in bold, and the
peptide epitope for the anti-SRp54 antibody used in this study is boxed
in both proteins. (B) Sequence comparison of the central putative RRM
in Drosophila SRp54 (dSRp54) compared to a central putative
RRM in a candidate SRp54 gene from C. elegans (cSRp54;
GenBank accession no. 1813908) and the N-terminal RRMs of the closest
RNA binding domains in the sequence database from a U1 snRNP 70K-like
protein (3), Drosophila U1 snRNP 70K (d70 kDa),
and human U1 snRNP 70K (h70 kDa). Black shading indicates amino acid
identity; gray shading depicts conservation.
|
|
There were two differences between the proteins. The human SRp54
contains 106 amino acids downstream of the SR domain not
present in the
Drosophila protein. The function of this domain
is unknown.
In addition, the two proteins differed by the sequences
within the
space separating the RRM and the SR domain. Within
this region of the
Drosophila protein, however, was a sequence
with strong
similarity to the domain in the human protein that
was the peptide
epitope for the anti-SRp54 antibody used in the
immunoprecipitation
experiments in Fig.
3 and
4 (peptide sequence
is boxed in Fig.
5A).
Thus, the isolated cDNA is
Drosophila SRp54,
and the
protein being identified by immunoprecipitation using
the peptide
antibody is likely to be that coded for by the identified
cDNA.
Interestingly, a computer search also revealed a putative
Caenorhabditis elegans SRp54 (GenBank accession no.
1813946 and
1813908). Sequence analysis showed that its
N-terminal RRM was
34.5% identical (70.2% similar) to the
Drosophila RRM and 36.6%
identical (73.2% similar)
to the human SRp54 RRM. This proposed
homolog also contained a
substantial SR domain. The potential
presence of SRp54 in divergent
organisms implies an important
role in RNA processing.
When the spacer regions of the two proteins were aligned, it became
apparent that the
Drosophila protein contains an additional
60 amino acids in the region between the RRM and the peptide epitope
compared to the human protein. Comparison of this sequence to
the
database indicated that this region could be considered a
second RRM.
Sequence comparison indicated that the closest related
RRM sequences
were those found in human and
Drosophila U1 snRNP
70K
proteins. The
Drosophila SRp54 sequence is 15.0 or 17.5%
identical
and 43.8 or 48.8% similar to
Drosophila or human
U1 70K protein,
respectively. It also shows 19.4% identity and 39.5%
similarity
to a human U1 70K-like protein (
3) within this
region. The
proposed SRp54 from
C. elegans also contains a
second putative
RRM with 31.3% identity and 57.5% similarity to the
Drosophila second RRM domain (Fig.
5B).
It is unusual to observe such a substantial sequence difference between
the human and
Drosophila versions of an SR protein.
Such a
difference raised the possibility of multiple forms of
either the human
or
Drosophila SRp54 protein, with or without
the second RRM.
To address this question, we performed RT-PCR
analysis of mRNA from
Drosophila S2 cells,
Drosophila third-instar
larvae (male and female), and HeLa cells. We used a 5' primer
specific
for the N-terminal RRM of each protein and a 3' primer
specific for the
common antigenic peptide. We also performed a
second amplification of
the
Drosophila RNAs, using a downstream
primer within the
second RRM. All of the reactions yielded a single
strong amplification
product (Fig.
6). Sequencing of the
RT-PCR
products confirmed their identities. The
Drosophila
RNA was larger
than the human RNA, using the peptide-specific primers
reflecting
the extra internal domain in the
Drosophila
protein. While the
RT-PCRs all yielded a single product, the
possibility remains
that other forms of SRp54 exist, possibly in
tissues not tested
here. We deduce from this experiment that there is a
single SRp54
mRNA in the tested RNA populations and that the
Drosophila SRp54
mRNA has an additional RRM compared to
the human protein.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 6.
RT-PCR analysis of SRp54 RNA in D. melanogaster and human cells reveals only a single SRp54 mRNA
species. Whole-cell RNA from S2 cells, Drosophila
third-instar larvae (male and female), or HeLa cells was subjected to
RT-PCR amplification using primers that flank the region between the
N-terminal RRMs and the epitopes of both proteins to detect potential
variants within the spacer region. The 5' primers were complementary to
a region within the N-terminal RRM domain of each gene. Two sets of 3'
primers were used. The first was complementary to nucleotides which
encode the peptide against which the anti-SRp54 antibody was raised
(labeled P). This region is present in both Drosophila and
human SRp54 (dSRp54 and hSRp54) and was used to amplify RNAs from all
sources. The expected products are 746 nt (using Drosophila
RNA) or 546 nt (using HeLa RNA). The second 3' primer was specific for
the Drosophila RNA and was complementary to the central
putative RRM domain (marked S). This amplification product is 569 nt.
Marker sizes are given in nucleotides, positions of the primers are
diagrammed below, and the sizes of the RT-PCR products are indicated at
the right.
|
|
SF1 does not bind the wild-type mle intron.
SF1
has been postulated to be a branch point binding protein that bridges
introns via binding to U2AF and U1 snRNP-associated proteins (2,
7, 8). Observation of SRp54 binding to the centrally located
C-rich pyrimidine tracts in the mle intron
raised the question of whether SRp54 obviated the need for
participation of SF1 as a splice site bridging factor for this small
intron. To investigate whether SF1 is used during mle
splicing, we immunoprecipitated UV cross-linked proteins and in
vitro-assembled spliceosomes, using antibodies specific for SF1 that
were raised against an N-terminal fragment (amino acids 2 to 320) of
human SF1 (5) that is highly conserved between humans and
Drosophila (22a). As a positive control, an
adenovirus-based substrate known to require SF1 (A62) was used. SF1 did
interact with the A62 substrate (Fig. 7A,
lane 6), as revealed by an immunoprecipitated, cross-linked band of 70 kDa. In contrast, when mle wild-type pre-mRNA was used in the reaction, no detectable cross-linked and immunoprecipitated band
was observed (Fig. 7A, lane 3). Therefore, SF1 does not appear to UV
cross-link to the mle intron. When the 3' splice site of the
mle intron was strengthened by the addition of a more
classical 3' pyrimidine tract downstream of the branch
point, SF1 cross-linking was detected (Fig. 7A, lane 5).

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 7.
SF1 does not UV bind to the wild-type (WT)
mle splicing substrate. (A) UV cross-linking of SF1. The
radiolabeled precursor RNAs indicated above the gel were subjected to
UV cross-linking as described for Fig. 2. mle precursor RNAs
are diagrammed in Fig. 1; the A62 construct is an adenovirus-based
substrate that has had its single intron internally deleted to 62 nt
(see Materials and Methods). Polyclonal antibodies against human SF1
protein were then added to immunoprecipitate cross-linked proteins.
Immunoprecipitated proteins were displayed on a sodium dodecyl
sulfate-10% polyacrylamide gel. The band corresponding to SF1 is
indicated. Markers are as shown. Pre-imm, preimmune serum. (B)
Immunoprecipitation of spliceosomes with anti-SF1 antibodies. The
indicated precursor RNAs were incubated under standard splicing
conditions in S2 extract for 7 min to permit assembly of complex A. Reaction mixtures were immunoprecipitated with the two anti-SF1 peptide
antibodies indicated. Radiolabeled RNAs within the immunoprecipitates
were displayed on denaturing urea gels. The amount of
immunoprecipitated RNA was quantified in the PhosphorImager;
relative density units are indicated below the lanes.
|
|
This experiment also addresses the appearance of a second band in the
UV cross-linking studies represented in Fig.
2A. When
mle+py was used
as the cross-linking substrate, a 70-kDa protein
was detected as
interacting with the pre-mRNA that was not present
in assays using
wild-type RNA (Fig.
2A, lane 7; Fig.
7A, lane
5). The experiment in
Fig.
7A suggests that this protein was SF1.
Thus, these experiments
suggest that SF1 does not cross-link to
the wild-type first intron from
the
mle gene unless a downstream
pyrimidine
tract has been introduced. Addition of a downstream
pyrimidine tract does not affect
mle
splicing. In this context,
however, the upstream
pyrimidine tracts are deleterious; i.e.,
the intron
assembles and splices better with a downstream pyrimidine
tract if the upstream tracts are mutated (
18). Combined with
the cross-linking results, this observation suggests that simultaneous
association of both SRp54 and SF1 with the
mle intron
is not optimal.
The absence of UV cross-linking of SF1 did not rule out the presence of
SF1 within the
mle spliceosome. To better assess this
possibility, complexes assembled on the wild-type and mutant
mle precursor RNAs were directly immunoprecipitated with two
SF1 antipeptide
antibodies (Fig.
7B). Antibodies against SF1 were able
to immunoprecipitate
considerable complex assembled on either the
adenovirus-based
small intron (A62) or the
mle intron to
which a strong pyrimidine
tract downstream of the branch
point had been added. In contrast,
little to no complex was
immunoprecipitated with the complexes
assembled on the wild-type
mle intron. Quantification of the amount
of radiolabeled RNA
precipitated indicated a 10- to 15-fold difference
between the ability
of the antibody to immunoprecipitate wild-type
complexes
versus complexes formed on a mutant precursor with a
strong downstream
pyrimidine tract. This observation suggests
that SF1
is not a component of the
mle spliceosome.
SRp54 and U2AF contact both the 5' and 3' ends of the
mle intron.
The association of SRp54, but not SF1,
with the mle pre-mRNA raised the possibility that either
SRp54 or U2AF65 bound to the centrally located C-rich
elements functions as a bridging factor(s) for this intron. To address
this question, immunoprecipitation of precleaved substrates was
used. In these experiments, radiolabeled substrates were incubated in
S2 extract for a short period of time sufficient for the assembly of
complex A but not subsequent assemblies and subjected to RNase
H-mediated cleavage using a DNA oligonucleotide complementary to a
region between the 5' splice site and C-rich
pyrimidine tracts. Following cleavage, antibodies
against SRp54 or U2AF were used to immunoprecipitate RNA
associated with the factors. If the protein that the antibody recognizes interacts with both sides of the intron, directly or indirectly, then both halves of the cleaved substrate should be immunoprecipitated. If, on the other hand, the factor makes contact with one of the ends, then only that part of the substrate should be
present in the immunoprecipitate. Figure
8 (lanes 3 and 6) shows that anti-SRp54
and anti-U2AF antibodies immunoprecipitated both the 3' and the 5'
halves of the mle wild-type intron. This ability was lost
and the signal dropped to background levels when the upstream elements
were mutated (Fig. 8, lanes 4 and 7). These results support the idea of
SRp54 and/or U2AF performing a bridging function in the mle
intron, such that one or both proteins contact sequences and/or factors
bound to the 5' and 3' splice sites. When a substrate that contained
only intron sequence from nt +1 to +38 (down to and including the
C-rich tracts) was used, both anti-SRp54 and anti-U2AF antibodies were
still able to immunoprecipitate the 5' half of the construct. This
observation indicates that the association of SRp54 and U2AF with the
5' end of the mle intron is independent of any contribution
from splicing signals present in the 3' half of the intron (branch
point, 3' pyrimidine tract, 3' splice site, or others). As
neither a deletion of the 5' splice site nor a mutation of this signal
affected SRp54 cross-linking (Fig. 2, lanes 4 and 5), it is possible
that SRp54 and U2AF interact with the upstream C-rich tracts first and
then make contact with other factors binding to the 5' splice site.

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 8.
SRp54 and U2AF contact both ends of the mle
intron. Radiolabeled RNA substrates were incubated in S2 extract for 7 min. Following the addition of RNase H and a DNA oligonucleotide
(GCAACATAACC) complementary to the region between the 5' splice site
and upstream pyrimidine stretches (nt +7 to +17 of the
intron; diagrammed at the bottom), the reaction mixtures were incubated
at 30°C for 3 min. They were next subjected to immunoprecipitation
using anti-SRp54 or anti-U2AF antibody. Immunoprecipitated RNAs were
prepared for electrophoresis on a 10% denaturing polyacrylamide gel.
The bands corresponding to precursor RNA or RNAs matching the 5' or 3'
halves of the substrate following RNase H-mediated cleavage are
indicated. Predicted products from each precursor used are depicted
below the gel. Marker sizes are given in nucleotides. WT, wild type.
|
|
The C-rich tracts need to be located near both the branch point and
the 5' splice site in order for spliceosome formation to proceed.
Another possible outcome of a bridging model using centrally located
intron signals is that the distance between the interacting cis elements might be critical. To test this possibility,
internal expansions were made in the 59-nt mle intron. An
NcoI site was introduced either between the C-rich tracts
and the branch point (BP65) or between the tracts and the 5' splice
site (5'65). The Drosophila troponin T intron sequence was
inserted at this site in BP65 or 5'65 to create BP80 and BP95 or 5'80
and 5'95, respectively. These introns have total lengths of 80 or 95 nt, compared to the 59 nt of the wild-type mle intron. The
ability of these various splicing substrates to be recognized was then
tested in spliceosome assembly assays. Figure
9A depicts the results obtained with the substrates containing an expansion between the upstream
pyrimidine-rich elements and the branch point in an
assembly assay. Even a moderate expansion of 6 nt began to inhibit
complex A formation, while larger insertions of 21 or 36 nt completely
abolished all assembly. Figure 9B displays the phenotypes of the 5'
splice site-pyrimidine tract expansions. These substrates
also lose the ability to form complex A when expanded. Thus, there is a
requirement for the C-rich tracts to be in close proximity to both the
5' splice site and branch point for maximal assembly of complex A.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 9.
Expanding the distance between the C-rich sequences and
either the 5' splice site or branch point inhibits spliceosome complex
assembly. (A and B) Spliceosome assembly of expanded mle
introns. The 59-nt wild-type mle intron [WT (59)] was
expanded to a total length of 65, 80, or 95 nt by additions between the
upstream pyrimidine tracts and the branch point (A, the BP
series) or between the 5' splice site and the pyrimidine
tracts (B, the 5' series). All constructs were incubated in S2 extract,
aliquots were taken at the indicated time points, and heparin was added
to a final concentration of 0.2 mg/ml. The reactions were then
displayed on native polyacrylamide gels in order to visualize
spliceosome complex assembly. Complexes A and H are indicated.
dTroponin T seq, Drosophila troponin T sequence. (C)
Spliceosome assembly of the mle intron mutated for the
upstream pyrimidine tracts. Assembly of the mle-py1,2
mutant (right) was compared to that of the wild type (left) in a native
assembly assay under the conditions described for panel A. (D)
Spliceosome assembly of expanded mle introns in which two
copies of the wild-type (ResWT) or mutant (ResMT) C-rich tracts were
inserted into the expansion cassette. This construct effectively
created an expanded intron containing four copies of the C-rich tracts
between the 5' splice site and branch point by duplicating the region
containing the C-rich tracts.
|
|
The assay used in Fig.
9 indicates a phenotype for the expansion
mutants during the assembly of complex A. We previously reported
assembly phenotypes for the upstream pyrimidine tract
mutations
on assembly of complex B, not complex A (
18). Our
previous experiments
used a high concentration of heparin (2.0 mg/ml)
to prevent nonspecific
associations prior to native gel
electrophoresis, whereas the
present experiments used a lower
concentration (0.2 mg/ml). Reanalysis
of the assembly phenotype of
upstream pyrimidine tract mutations
on spliceosome assembly
with the lower heparin concentration revealed
that the major effect of
the mutations was on complex A, not complex
B, formation (Fig.
9C). The
lower-heparin conditions also caused
the disappearance of a wild-type
complex running just above complex
H that is dependent on the upstream
C-rich tracts, ATP, and U1
and U2 snRNPs for formation (data not
shown), and which presumably
reflects a form of complex A that has lost
U2 snRNPs. This observation
suggests that complex A formed on the
mle intron partially disassociates
in high heparin, perhaps
reflecting the small size of the intron
and the restrictions such size
imposes on stable complex assembly.
Furthermore, it indicates that the
upstream pyrimidine tracts
are required for complex A
formation and the introduction of U2
snRNPs into the spliceosome.
To see if the intron expansions could be rescued by the
introduction of additional C-rich elements, we created a set of
constructs
in which two copies of the repeat, both wild type and
mutant,
were introduced into one of the
mle intron
expansions. This addition
created a minimally expanded intron with four
copies of the element
between the 5' splice site and branch point.
Analysis of spliceosome
assembly of the two constructs indicated that
the additional repeats
provided better assembly than a mutant construct
but did not restore
assembly to the wild-type level (Fig.
9D). This
result is what
would be expected if factor(s) bound to the C-rich
tracts were
required to simultaneously contact unique factors bound on
either
side. This result also supports earlier reported observations
that assembly of complex A on the
mle intron requires both a
5'
and 3' splice site (
29) and suggested that the intron is
recognized
as a unit of splice sites and internal C-rich
pyrimidine tracts.
Expanding the distance between the upstream pyrimidine
tracts and either the branch point or 5' splice site depresses factor
association with the 5' splice site.
The assembly results
discussed above indicate that the upstream pyrimidine
tracts are necessary for the association of U2 snRNPs with the
spliceosome so as to form complex A. To assess the requirement for the
upstream tracts on events at the 5' splice site, we analyzed the
ability of splicing factors (e.g., U1 snRNP) to bind to and protect the
5' splice site. Expansion of the mle intron on either side
of the upstream pyrimidine tracts lowered the ability of
factors to protect the 5' splice site against digestion with RNase H
and a complementary oligonucleotide (Fig.
10). Expansion upstream of the C-rich
tracts severely inhibited binding of factors to the 5' splice site
(22% protection compared to the wild type), whereas expansion
downstream of the tracts afforded 50% of the protection given by the
wild-type substrate. We have previously reported that mutation of the
upstream tracts severely inhibited protection of the 5' splice site and
that the protection was U1 dependent (18). Therefore, the
upstream tracts are necessary for the binding of both U2 and U1 snRNPs
to the ends of the intron.

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 10.
Association of factors with the 5' splice site is
depressed by expanding the distance between the upstream
pyrimidine tracts and either the 5' splice site or branch
point. To monitor 5' splice site protection, RNase H along with an
oligonucleotide complementary to the 5' splice site (nt 4 to +13) was
added during an assembly reaction using the depicted expansion
constructs. Time points indicate time (minutes) of addition of the
oligonucleotide. RNA products were displayed on a 5% denaturing
polyacrylamide gel. Protection is indicated by the appearance of a band
of the length of precursor RNA and a reduction in the amount of
cleavage product. Precursor RNAs are as in Fig. 7. Anticipated cleavage
and protection products are diagrammed below the gel. Marker sizes are
given in nucleotides. WT, wild type.
|
|
 |
DISCUSSION |
Examination of the factors involved in pre-mRNA splicing has
revealed an amazing conservation from yeasts to humans. Both snRNPs and
other factors are conserved, suggesting that constitutive recognition
of splicing signals may be very similar for all introns. U2AF is one
such conserved factor participating in one of the earliest steps of
recognition by binding to sequences at the 3' end of the intron and
facilitating binding of U2 snRNPs to the branch point (17, 30, 35,
36). Another conserved protein is SF1, which binds to the branch
point region (5, 7). U2AF and SF1 cooperatively interact to
recognize the branch point and pyrimidine tract
(8). In the yeast Saccharomyces cerevisiae, genetic interactions have established that SF1 acts to bridge the
intron by making contacts with both U2AF and proteins bound to U1
snRNPs (2). Because the U1 snRNP proteins implicated in
SF1-mediated bridging have not yet been observed in vertebrates, it is
unclear if SF1 plays this role in assembly of the mammalian spliceosome. The conservation between the yeast and mammalian proteins,
however, argues that SF1-mediated bridging should be universal.
Intron size and sequence diverges greatly across the eucaryotic
kingdom. Typical vertebrate introns are large and contain noticeable
pyrimidine tracts in the region between the branch point
and 3' splice site (16). These tracts are the binding site
for U2AF (35). In contrast, many nonvertebrates have small introns, many of which are so small that they cannot function in a
vertebrate system (14, 29). In addition, they frequently lack recognizable pyrimidine tracts downstream of the
branch point (23). Here we suggest that one of these introns
from the Drosophila mle gene may utilize a mode of early
assembly different from that defined for other introns, in either
yeasts or vertebrates.
The mle intron has unusual C-rich pyrimidine
tracts located in the short interval between the 5' splice site and
branch point that are required for maximal spliceosome assembly and the
binding of U2AF and the SR protein SRp54. Unlike most SR proteins,
SRp54 contacts U2AF via its large subunit (U2AF65) rather
than its small subunit (U2AF35) (37). Our data
suggest that this mode of interaction could potentially serve to create
a bridge for small introns, obviating the need for the involvement of
SF1. Bridging was revealed by the requirement for the sequence and
location of the C-rich tracts for the association of U1 and U2 snRNPs,
as well as the ability of SRp54 and U2AF to contact both the 5' and 3'
splice sites, either directly or indirectly. This bridging
appeared to operate in the absence of SF1 because, in contrast to
spliceosomes formed with precursor RNAs with normal 3'
pyrimidine tracts, mle spliceosomes could not be
immunoprecipitated with anti-SF1 antibodies.
The mle intron lacks a classical pyrimidine
tract between the branch point and 3' splice site. When such a
site was added, the intron functioned; but in this context,
the upstream C-rich tracts were inhibitory for assembly and activity
(18), suggesting alternative competitive modes of early
recognition. Addition of the downstream tracts was accompanied by the
ability to detect 10- to 15-fold higher levels of immunoprecipitation
of the mle spliceosome with antibodies specific for SF1,
suggesting that SF1 contacts the mle intron only in the
presence of downstream tracts. Furthermore, these results suggest that
simultaneous association of SRp54 and SF1 with the intron is not
optimal for assembly or activity.
Taken together, these observations suggest that when introns are very
small, U2AF and SRp54 may function to provide early recognition and
intron bridging. SR proteins have been observed to provide both
cross-exon and cross-intron interactions in a number of vertebrate
pre-mRNAs (reviewed in references 9, 13, 22, and
25). Models for these interactions invoke
associations with U2AF that involve the SR domain of the small subunit
of U2AF. In contrast, SF1 bridging models invoke an interactions with
the large subunit of U2AF (2). The relationship between the
two modes of bridging has been unclear.
Our results suggest that individual introns may differ in the mechanism
of bridging employed and raise the possibility of gene-specific
early assembly. In S. cerevisiae, branch points are
well conserved but pyrimidine tracts are relatively
rare and play only a weak role in intron recognition. Accordingly,
MUD2 (the gene encoding the U2AF65 homolog) is
inessential for viability; instead SF1 (BBP) plays a pivotal role
(2). In contrast, in vertebrates, U2AF is required and binds
to a prominent splicing signal, the 3' polypyrimidine tract
(36) and also contacts the branch site (30).
Bridging is afforded by SR proteins and presumably by SF1. Our data
suggest a third scenario operating in small introns such as those in
Drosophila or C. elegans. In these cases, U2AF
and SRp54 function to bind to pyrimidine tracts in the
vicinity of the branch point, thereby providing intron bridging. One
scenario for this bridging is that SRp54, via its ability to bind the
upstream pyrimidine tracts in the mle intron,
facilitates U2AF binding upstream of the branch point and positions the
small subunit of U2AF to make optimal interactions with the U1 snRNP
70K protein (Fig. 11A). This model presents the mle intron as a recognition unit equivalent to
the SR-mediated recognition units postulated in exon definition in vertebrates.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 11.
Suggested models for participation of U2AF and SRp54 in
splice site bridging. In model A, the SR-rich small subunit of
Drosophila U2AF (dU2AF) contacts the U1 snRNP 70K
protein to affect interactions across a small intron. Use of
pyrimidine tracts upstream of the branch point is
postulated to position U2AF such that participation of SF1 or other
normal bridging proteins is unnecessary. In model B, the SR protein
SRp54 is used to make contacts with factors bound to the 5' splice
site, whereas the small subunit of U2AF is used to bridge the
downstream exon. This model suggests how both intron and exon
definition could operate in adjacent areas of a single pre-mRNA.
|
|
Also possible, however, is an alternative mechanism whereby U2AF
participates in simultaneous interactions across a neighboring exon and
intron. In recent years, both intron and exon bridging models for
recognition of splice sites in multiexon RNAs have been proposed
(1, 2, 6, 9, 25, 27, 38). In general, organisms with small
introns are thought to operate via intron bridging, whereas in
organisms with large introns, exon bridging is proposed. D. melanogaster presents an example of an organism with a split
exon/intron organization such that small and large introns are mixed
within individual transcription units. The mle gene is one
such split unit. The intron studied in this report is quite small; the
adjacent intron is considerable larger. Such mixed architecture
presents problems for models of splice site pairing that use either
consistent exon or intron bridging. The results in this study suggest a
mechanism whereby both could occur simultaneously (Fig. 11B). As
this model depicts, a small upstream intron using a bridging factor
such as SRp54 or SF1 that contacts the large subunit of U2AF would
permit simultaneous interaction of the small subunit of U2AF with
factors binding the downstream exon.
As part of this study, we sequenced the Drosophila homolog
of SRp54. While considerable conservation was found within both the RRM
and SR domains, the Drosophila protein contained extra sequence within the spacer region. Analysis of this sequence revealed that it resembled an RRM. In fact, computer searches attempting to find
motifs similar to this sequence yielded the RRM regions of both the
human and Drosophila U1 snRNP 70-kDa proteins. The proposed
C. elegans SRp54 also contains this second RRM domain, suggesting that in these nonvertebrates, the protein may possess some
unique functions. The exact role of this second RRM is unknown. It could affect the affinity and specificity of the first RRM, it
could function in protein-protein interactions, or it could perform a
completely unique activity related to small-intron recognition (11, 21, 24, 34). Experiments comparing and contrasting the
Drosophila and human proteins should lend insight into the function of this protein.
 |
ACKNOWLEDGMENTS |
We thank N. Chaudhary for generous gifts of SRp54-specific
antibodies and discussions about the protein, and we thank R. Sierra for excellent technical experience and for sequencing
Drosophila SRp54.
C.K. and S.M.B. were supported by a fellowship from the Robert A. Welch
Foundation and NIH RO1 GM38526.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Verna and Marrs
McLean Department of Biochemistry, Program in Cell and Molecular
Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX
77030. Phone: (713) 798-5758. Fax: (713) 795-5487. E-mail:
sberget{at}bcm.tmc.edu.
 |
REFERENCES |
| 1.
|
Abovich, N.,
X. C. Liao, and M. Rosbash.
1994.
The yeast MUD2 protein: an interaction with PRP11 defines a bridge between commitment complexes and U2 snRNP addition.
Genes Dev.
8:843-854[Abstract/Free Full Text].
|
| 2.
|
Abovich, N., and M. Rosbash.
1997.
Cross-intron bridging interactions in the yeast commitment complex are conserved in mammals.
Cell
89:403-412[Medline].
|
| 3.
|
Adams, D. S.,
Q. Li,
T. Szabo,
X. Tan,
S. Pero, and J. K. Czop.
1996.
Cloning and characterization of a family of cDNAs from human histiocyte macrophage cells encoding a glycine/arginine-rich basic protein related to the highly conserved 70 kD U1-snRNP protein.
GenBank accession no. 1174217 annotation.
|
| 4.
|
Adams, M. D.,
D. Z. Rudner, and D. C. Rio.
1996.
Biochemistry and regulation of pre-mRNA splicing.
Curr. Opin. Cell Biol.
8:331-339[Medline].
|
| 5.
|
Arning, S.,
P. Gruter,
G. Bilbe, and A. Krämer.
1996.
Mammalian splicing factor SF1 is encoded by variant cDNAs and binds to RNA.
RNA
2:794-810[Abstract].
|
| 6.
|
Berget, S. M.
1995.
Exon recognition in vertebrate splicing.
J. Biol. Chem.
2:2411-2414.
|
| 7.
|
Berglund, J. A.,
K. Chua,
N. Abovich,
R. Reed, and M. Rosbash.
1997.
The splicing factor BBP interacts specifically with the pre-mRNA branchpoint sequence UACUAAC.
Cell
89:781-787[Medline].
|
| 8.
|
Berglund, J. A.,
N. Abovich, and M. Rosbash.
1998.
A cooperative interaction between U2AF65 and mBBP/SF1 facilitates branchpoint region recognition.
Genes Dev.
12:858-867[Abstract/Free Full Text].
|
| 9.
|
Black, D. L.
1995.
Finding splice sites in a wilderness of RNA.
RNA
1:763-771[Medline].
|
| 10.
|
Champion-Arnaud, P.,
O. Gozani,
L. Palandijian, and R. Reed.
1995.
Accumulation of a novel spliceosomeal complex on pre-mRNAs containing branch site mutations.
Mol. Cell. Biol.
15:5750-5756[Abstract].
|
| 11.
|
Chandler, S. D.,
A. Mayeda,
J. M. Yeakley,
A. R. Krainer, and X. D. Fu.
1997.
RNA splicing specificity determined by the coordinated action of RNA recognition motifs in SR proteins.
Proc. Natl. Acad. Sci. USA
94:3596-3601[Abstract/Free Full Text].
|
| 12.
|
Chaudhary, N.,
C. McMahon, and G. Blobel.
1991.
Primary structure of a human arginine-rich nuclear protein that colocalizes with spliceosome components.
Proc. Natl. Acad. Sci. USA
88:8189-8193[Abstract/Free Full Text].
|
| 13.
|
Fu, X.-D.
1995.
The superfamily of arginine/serine rich splicing factors.
RNA
1:663-680[Medline].
|
| 14.
|
Guo, M.,
P. C. H. Lo, and S. M. Mount.
1993.
Species-specific signals for the splicing of a short Drosophila intron in vitro.
Mol. Cell. Biol.
13:1104-1118[Abstract/Free Full Text].
|
| 15.
|
Guthrie, C.
1991.
Messenger RNA splicing in yeast: clues to why the spliceosome is a ribonucleoprotein.
Science
253:157-163[Abstract/Free Full Text].
|
| 16.
|
Hawkins, J. D.
1988.
A survey on intron and exon lengths.
Nucleic Acids Res.
16:9893-9908[Abstract/Free Full Text].
|
| 17.
|
Kanaar, R.,
S. E. Roche,
E. L. Beall,
M. R. Green, and D. C. Rio.
1993.
The conserved pre-mRNA splicing factor U2AF from Drosophila: requirement for viability.
Science
262:569-572[Abstract/Free Full Text].
|
| 18.
|
Kennedy, C. F., and S. M. Berget.
1997.
Pyrimidine tracts between the 5' splice site and branch point facilitate splicing and recognition of a small Drosophila intron.
Mol. Cell. Biol.
17:2774-2780[Abstract].
|
| 19.
|
Krämer, A.
1992.
Purification of splicing factor SF1, a heat-stable protein that functions in the assembly of a presplicing complex.
Mol. Cell. Biol.
12:4545-4552[Abstract/Free Full Text].
|
| 20.
|
Krämer, A.
1996.
The structure and function of proteins involved in mammalian pre-mRNA splicing.
Annu. Rev. Biochem.
65:367-409[Medline].
|
| 21.
|
Lu, J., and K. B. Hall.
1995.
An RBD that does not bind RNA: NMR secondary structure determination and biochemical properties of the C-terminal RNA binding domain from the human U1A protein.
J. Mol. Biol.
247:739-752[Medline].
|
| 22.
|
Manley, J. L., and R. Tacke.
1996.
SR proteins and splicing control.
Genes Dev.
10:16569-1579.
|
| 22a.
| Mazroui, R., and A. Krämer. Unpublished data.
|
| 23.
|
Mount, S. M.,
C. Burks,
G. Hertz,
G. D. Stormo,
O. White, and C. Fields.
1992.
Splicing signals in Drosophila: intron size, information content, and consensus sequences.
Nucleic Acids Res.
20:4255-4262[Abstract/Free Full Text].
|
| 24.
|
Perez, I.,
J. G. McAfee, and J. G. Patton.
1997.
Multiple RRMs contribute to RNA binding specificity and affinity for polypyrimidine tract binding protein.
Biochemistry
36:11881-11890[Medline].
|
| 25.
|
Reed, R.
1996.
Initial splice site recognition and pairing during pre-mRNA splicing.
Curr. Opin. Genet. Dev.
6:215-220[Medline].
|
| 26.
|
Rio, D. C.
1993.
Splicing of pre-mRNA: mechanism, regulation and role in development.
Curr. Opin. Genet. Dev.
3:574-584[Medline].
|
| 27.
|
Robberson, B. L.,
G. J. Cote, and S. M. Berget.
1990.
Exon definition may facilitate splice site selection in RNAs with multiple exons.
Mol. Cell. Biol.
10:84-94[Abstract/Free Full Text].
|
| 28.
|
Singh, R.,
J. Valcárcel, and M. R. Green.
1995.
Distinct binding specificities and functions of higher eukaryotic polypyrimidine-tract binding proteins.
Science
268:1173-1176[Abstract/Free Full Text].
|
| 29.
|
Talerico, M., and S. M. Berget.
1994.
Intron definition in splicing of small Drosophila introns.
Mol. Cell. Biol.
14:3434-3445[Abstract/Free Full Text].
|
| 30.
|
Valcárcel, J.,
R. K. Gaur,
R. Singh, and M. R. Green.
1996.
Interaction of U2AF65 RS region with pre-mRNA branch point and promotion of base pairing with U2 snRNA.
Science
273:1706-1709[Abstract/Free Full Text].
|
| 31.
|
Valcárcel, J., and M. R. Green.
1996.
The SR protein family: pleiotropic functions in pre-mRNA splicing.
Trends Biochem. Sci.
21:296-301[Medline].
|
| 32.
|
Wang, Z.,
H. M. Hoffman, and P. J. Grabowski.
1995.
Intrinsic U2AF binding is modulated by exon enhancer signals in parallel with changes in splicing activity.
RNA
1:21-35[Abstract].
|
| 33.
|
Wu, J. Y., and T. Maniatis.
1993.
Specific interactions between proteins implicated in splice site selection and regulated alternative splicing.
Cell
75:1061-1070[Medline].
|
| 34.
|
Xu, R. M.,
I. Jokhan,
X. Cheng,
A. Mayeda, and A. R. Krainer.
1997.
Crystal structure of human UP1, the domain of hnRNP A1 that contains two RNA recognition motifs.
Structure
5:559-570[Medline].
|
| 35.
|
Zamore, P. D., and M. R. Green.
1989.
Identification, purification and characterization of U2 small nuclear ribonucleoprotein auxiliary factor.
Proc. Natl. Acad. Sci. USA
86:9243-9247[Abstract/Free Full Text].
|
| 36.
|
Zamore, P. D., and M. R. Green.
1991.
Biochemical characterization of U2 snRNP auxiliary factor: an essential pre-mRNA splicing factor with a novel intracellular distribution.
EMBO J.
10:207-214[Medline].
|
| 37.
|
Zhang, W.-J., and J. Y. Wu.
1996.
Functional properties of p54, a novel SR protein active in constitutive and alternative splicing.
Mol. Cell. Biol.
16:5400-5408[Abstract].
|
| 38.
|
Zuo, P., and T. Maniatis.
1996.
The splicing factor U2AF35 mediates critical protein-protein interactions in constitutive and enhancer-dependent splicing.
Genes Dev.
10:1356-1368[Abstract/Free Full Text].
|
Molecular and Cellular Biology, September 1998, p. 5425-5434, Vol. 18, No. 9
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Sridharan, V., Singh, R.
(2007). A Conditional Role of U2AF in Splicing of Introns with Unconventional Polypyrimidine Tracts. Mol. Cell. Biol.
27: 7334-7344
[Abstract]
[Full Text]
-
Wu, J. Y., Kar, A., Kuo, D., Yu, B., Havlioglu, N.
(2006). SRp54 (SFRS11), a Regulator for tau Exon 10 Alternative Splicing Identified by an Expression Cloning Strategy.. Mol. Cell. Biol.
26: 6739-6747
[Abstract]
[Full Text]
-
Collins, L., Penny, D.
(2006). Investigating the Intron Recognition Mechanism in Eukaryotes. Mol Biol Evol
23: 901-910
[Abstract]
[Full Text]
-
Kupfer, D. M., Drabenstot, S. D., Buchanan, K. L., Lai, H., Zhu, H., Dyer, D. W., Roe, B. A., Murphy, J. W.
(2004). Introns and Splicing Elements of Five Diverse Fungi. Eukaryot Cell
3: 1088-1100
[Abstract]
[Full Text]
-
Sakashita, E., Tatsumi, S., Werner, D., Endo, H., Mayeda, A.
(2004). Human RNPS1 and Its Associated Factors: a Versatile Alternative Pre-mRNA Splicing Regulator In Vivo. Mol. Cell. Biol.
24: 1174-1187
[Abstract]
[Full Text]
-
Li, J., Hawkins, I. C., Harvey, C. D., Jennings, J. L., Link, A. J., Patton, J. G.
(2003). Regulation of Alternative Splicing by SRrp86 and Its Interacting Proteins. Mol. Cell. Biol.
23: 7437-7447
[Abstract]
[Full Text]
-
MACMORRIS, M., BROCKER, C., BLUMENTHAL, T.
(2003). UAP56 levels affect viability and mRNA export in Caenorhabditis elegans. RNA
9: 847-857
[Abstract]
[Full Text]
-
Li, J., Barnard, D. C., Patton, J. G.
(2002). A Unique Glutamic Acid-Lysine (EK) Domain Acts as a Splicing Inhibitor. J. Biol. Chem.
277: 39485-39492
[Abstract]
[Full Text]
-
Romfo, C. M., Alvarez, C. J., van Heeckeren, W. J., Webb, C. J., Wise, J. A.
(2000). Evidence for Splice Site Pairing via Intron Definition in Schizosaccharomyces pombe. Mol. Cell. Biol.
20: 7955-7970
[Abstract]
[Full Text]
-
Mount, S. M., Salz, H. K.
(2000). Pre-Messenger RNA Processing Factors in the Drosophila Genome. JCB
150: 37-44
[Full Text]
-
Carlo, T., Sierra, R., Berget, S. M.
(2000). A 5' Splice Site-Proximal Enhancer Binds SF1 and Activates Exon Bridging of a Microexon. Mol. Cell. Biol.
20: 3988-3995
[Abstract]
[Full Text]
-
Barnard, D. C., Patton, J. G.
(2000). Identification and Characterization of a Novel Serine-Arginine-Rich Splicing Regulatory Protein. Mol. Cell. Biol.
20: 3049-3057
[Abstract]
[Full Text]
-
Cooke, C., Hans, H., Alwine, J. C.
(1999). Utilization of Splicing Elements and Polyadenylation Signal Elements in the Coupling of Polyadenylation and Last-Intron Removal. Mol. Cell. Biol.
19: 4971-4979
[Abstract]
[Full Text]